Accès gratuit
Numéro
Thérapie
Volume 61, Numéro 4, Juillet-Août 2006
XXIes Rencontres Nationales de Pharmacologie Clinique de Giens, 16-18 octobre 2005
Page(s) 297 - 304
Section Pharmacovigilance/Pharmacovigilance
DOI https://doi.org/10.2515/therapie:2006057
Publié en ligne 7 février 2007
  1. Beyens MN, Guy C, Ratrema M, et al. Prescription médicamenteuse pendant la grossesse en France : étude HIMAGE. Thérapie 2003; 58: 505-11
  2. Felix RJ, Jones KL, Johnson KA, et al. Post marketing surveillance for drug safety in pregnancy: the organization of teratology information services project. Birth Defects Research 2004; 70: 944-7
  3. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, et al. Prescription of drugs during pregnancy in France. Lancet 2000; 356: 1735-6
  4. Brocklebank JC, Ray WA, Federspiel CF, et al. Drug prescribing during pregnancy. A controlled study of Tennessee Medicaid recipients. Am J Obstet Gynecol 1978; 132: 235-44 [PubMed]
  5. Piper JM, Baum C, Kennedy DL. Pescription drug use before and during pregnancy in a Medicaid population. Am J Obstet Gynecol 1987; 157: 148-56 [CrossRef] [PubMed]
  6. Rubin JD, Ferencz C, Loffredo C. Use of prescription and non-prescription drugs in pregnancy: the Baltimore-Washington Infant Study Group. J Clin Epidemiol 1993; 46: 581-9 [CrossRef] [PubMed]
  7. Boethius G. Recording of drug prescriptions in the county of Jamtland, Sweden. II. Drug exposure of pregnant women in relation to course and outcome of pregnancy. Eur J Clin Pharmacol 1977; 12: 37-43 [CrossRef] [PubMed]
  8. Guittin P, Soubrie C, Autret E, et al. Toxicologie de la reproduction : valeurs prédictives des modèles expérimentaux. Thérapie 1998; 53: 355-63
  9. Elefant E, Sainte-Croix A. Evaluation du risque médicamenteux chez la femme enceinte : méthodologie d'evaluation et gestion du risque. Thérapie 1997; 52: 307-11
  10. Chauvenet M, Rimailho A, Hoog-Labouret N. Methodology for the evaluation of drugs in pregnant women. Thérapie 2003; 58: 247-58 [CrossRef] [EDP Sciences]
  11. Conférence Internationale d'Harmonisation, ICH. http://www.ich.org
  12. Guideline on risk management systems for medicinal products for human use, EMEA/CHMP/96268/2005 http://www.emea.eu.int
  13. Loi 2004-806 du 9 août 2004 du Code de Santé Publique http://www.legifrance.gouv.fr
  14. Note for guidance on the exposure to medicinal products during pregnancy: need for post-authorisation data, EMEA/CHMP/1889/04 http://www.emea.eu.int
  15. Weinstein RM, Goldfield M. Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry 1975, 132: 529-31
  16. Jacobson SJ, Jones K, Johnson K, et al. Prospective multicenter study of pregnancy after lithium exposure during first trimester. Lancet 1992; 339: 530-3
  17. Clementi M, Di Gianantonio E, Ornoy A. Teratology information services in Europe and their contribution to the prevention of congenital anomalies. Community Genet 2002; 5: 8-12 [CrossRef] [PubMed]
  18. Robert-Gnansia E. Méthodes d'évaluation des risques liés aux prises médicamenteuses pendant la grossesse. Avantages et limites de l'épidémiologie, interprétation des résultats. Thérapie 2002; 57: 175-80
  19. Koren G. Clinical trials during pregnancy: Challenges and solutions. In Paediatric Clinical Pharmacology, p 359-365, 2005 edited by E. Jacqz-Aigrain, I Choonara, Fontis Media Editors
  20. Bates DW, Pappius EM, Kuperman GJ, et al. Medinfo. Measuring and improving quality using information systems 1998; 9: 814-8
  21. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483-6 [CrossRef] [PubMed]